Bruno Odermatt
Gründer bei Value Solutions Group
Profil
Bruno Odermatt is the founder of Value Solutions Group, which was founded in 2000.
Currently, he is a Director at 1CryoBio AG and 3Brain AG.
In the past, he worked as the Chief Financial Officer at Prionics AG.
He also worked as an Assurance Manager at Deloitte & Touche Ltd.
from 1989 to 1995 and as a Principal at KPMG Corporate Finance (Switzerland) from 1995 to 2000.
Aktive Positionen von Bruno Odermatt
| Unternehmen | Position | Beginn |
|---|---|---|
| Value Solutions Group | Gründer | 03.05.2011 |
1CryoBio AG
 1CryoBio AG Medical SpecialtiesHealth Technology 1CryoBio AG engaged in the development, production, and market of innovative lab ware for cryogenic storage. It offers FlexiQuot, a dividable cryotubes that optimize frozen sample storage. The company was founded on February 13, 2014 and is headquartered in Root, Switzerland. | Direktor/Vorstandsmitglied | - |
3Brain AG
 3Brain AG Information Technology ServicesTechnology Services 3Brain AG is a Swiss company that specializes in improving in vitro cell-based screening outputs to find new treatments for brain diseases. The private company is located in Wädenswil, Switzerland. The company is the world's first company to connect cells with sophisticated biosignal processing microchips in vitro. The CEO of the company is Mauro Gandolfo. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Bruno Odermatt
| Unternehmen | Position | Ende |
|---|---|---|
| KPMG Corporate Finance (Switzerland) | Corporate Officer/Principal | 01.01.2000 |
Deloitte & Touche Ltd.
 Deloitte & Touche Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Deloitte LLP (New York), Deloitte & Touche Ltd. is a company based in Nicosia, Cyprus. The Cypriot company was founded by Markos Drakos. | Corporate Officer/Principal | 01.01.1995 |
Prionics AG
 Prionics AG Medical SpecialtiesHealth Technology Prionics AG engages in the research in as well as the development, production, and distribution of diagnostic solutions for farm animal diseases. It focuses on diseases that can be transmitted from animals to human beings such as mad cow's disease and other prion diseases. The company was founded by Bruno Oesch and Markus Moser on February 27, 1997 and is headquartered in Schlieren, Switzerland. | Finanzdirektor/CFO | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Prionics AG
Prionics AG Medical SpecialtiesHealth Technology Prionics AG engages in the research in as well as the development, production, and distribution of diagnostic solutions for farm animal diseases. It focuses on diseases that can be transmitted from animals to human beings such as mad cow's disease and other prion diseases. The company was founded by Bruno Oesch and Markus Moser on February 27, 1997 and is headquartered in Schlieren, Switzerland. | Health Technology |
Deloitte & Touche Ltd.
Deloitte & Touche Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Deloitte LLP (New York), Deloitte & Touche Ltd. is a company based in Nicosia, Cyprus. The Cypriot company was founded by Markos Drakos. | Commercial Services |
| KPMG Corporate Finance (Switzerland) | |
| Value Solutions Group | |
1CryoBio AG
1CryoBio AG Medical SpecialtiesHealth Technology 1CryoBio AG engaged in the development, production, and market of innovative lab ware for cryogenic storage. It offers FlexiQuot, a dividable cryotubes that optimize frozen sample storage. The company was founded on February 13, 2014 and is headquartered in Root, Switzerland. | Health Technology |
3Brain AG
3Brain AG Information Technology ServicesTechnology Services 3Brain AG is a Swiss company that specializes in improving in vitro cell-based screening outputs to find new treatments for brain diseases. The private company is located in Wädenswil, Switzerland. The company is the world's first company to connect cells with sophisticated biosignal processing microchips in vitro. The CEO of the company is Mauro Gandolfo. | Technology Services |
